Skip to content

Yang Qu

3 papers in the library · 43 citations · publishing 2023-2026

Papers

Sort Most recent Most cited

Dose-dependent adverse events of esketamine in treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials.

Frontiers in Pharmacology 2026 Yang Qu, Shujin Li, Li Tian et al.

This study systematically evaluated the safety profile of esketamine for treatment-resistant depression through a meta-analysis, focusing on dose-dependent adverse events and associated risk factors to inform precision dosing. PubMed, Embase, the Cochrane Library, the Mainland China Biomedical Literature Database (CBM), the China National Knowledge Infrastructure (CNKI) and Wanfang databases...

Biosynthesis of kratom opioids

New Phytologist July 30, 2023 Kyunghee Kim, Mohammadamin Shahsavarani, Jorge Jonathan Oswaldo Garza-García et al. 43 citations

Summary Mitragynine, an analgesic alkaloid from the plant Mitragyna speciosa (kratom), offers a safer alternative to clinical opioids such as morphine, owing to its more favorable side effect profile. Although kratom has been traditionally used for stimulation and pain management in Southeast Asia, the mitragynine biosynthesis pathway has remained elusive. We embarked on a search for...

DOI: 10.1111/nph.19162 (opens in new tab) Mitragyna speciosa Enol methyltransferase Mitragynine microbial biosynthesis Monoterpenoid indole alkaloid +6

Ayahuasca plant genomes reveal retrotransposon-derived centromeres and contrasting routes to DMT and β-carbolines

Ruiyi Qiu, Scott Galeung Alexander Mann, Thiago Nascimento et al.

Ayahuasca, used religiously for centuries by Amazonian Indigenous peoples and increasingly studied for its therapeutic potential, owes its psychoactivity to two plants: Psychotria viridis supplies N,N-dimethyltryptamine (DMT), whereas Banisteriopsis caapi supplies beta-carbolines that render DMT orally active. Here we show that the two plants have distinct genome histories: P. viridis is...